iTeos Therapeutics, Inc. (ITOS)
NASDAQ: ITOS · Real-Time Price · USD
10.13
+0.03 (0.30%)
At close: Aug 13, 2025, 4:00 PM
10.12
-0.01 (-0.10%)
After-hours: Aug 13, 2025, 4:35 PM EDT
iTeos Therapeutics Employees
iTeos Therapeutics had 173 employees as of December 31, 2024. The number of employees increased by 16 or 10.19% compared to the previous year.
Employees
173
Change (1Y)
16
Growth (1Y)
10.19%
Revenue / Employee
n/a
Profits / Employee
-$1,170,006
Market Cap
447.80M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ITOS News
- 22 days ago - ITEOS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iTeos Therapeutics, Inc. - ITOS - Business Wire
- 23 days ago - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of iTeos Therapeutics, Inc. - PRNewsWire
- 23 days ago - iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right - GlobeNewsWire
- 2 months ago - iTeos Therapeutics Announces Its Intention to Wind Down Operations - GlobeNewsWire
- 3 months ago - iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients - GlobeNewsWire
- 3 months ago - iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 5 months ago - iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025 - GlobeNewsWire
- 5 months ago - iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - GlobeNewsWire